BioCentury
ARTICLE | Clinical News

FDA grants Priority Review to NDA for Jazz’s Vyxeos

June 2, 2017 4:03 PM UTC

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said FDA accepted and granted Priority Review to an NDA for Vyxeos (CPX-351) to treat acute myelogenous leukemia (AML). Its PDUFA date is Sept. 30.

Jazz completed its rolling NDA submission for Vyxeos on March 31 (see BioCentury, April 17)...

BCIQ Company Profiles

Jazz Pharmaceuticals plc

BCIQ Target Profiles

Topoisomerase II (TOP2)